News

A new approach to ventilation could help reduce airborne nosocomial transmission

Madeline King, PharmD, discusses her research presented at ECCMID 2019 on pre-operative asymptomatic bacteriuria and appropriateness of aztreonam usage.

Here is a look at infectious disease-related US Food and Drug Administration news from the week of April 14, 2019.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

A new look into pediatric telemedicine prescribing shows some concerning revelations about prescribing patterns.

Sexual risk behavior was significantly lower among men in community supervision programs who participated in couples-based intervention, in a recent study.

Following a 2018 outbreak in the US of acute flaccid myelitis, a new paper calls for research into the causes of this surge of a usually rare disease.

In a new trial, an experimental antibody suppressed HIV in patients on short-term pause from their daily antiretroviral therapy regimens.

The Early Sepsis Indicator is hematology-based cellular biomarker designed to help emergency department physicians identify patients with sepsis or at an increased risk of developing sepsis.

This In the Literature piece details a study evaluating the effects of ID consultation for OPAT patients.

A study using monkeys provides an intriguing glimpse of the possibilities of using CRISPR gene editing technology to knock out HIV reserves in humans.

A shortage of infectious disease physicians should have us all concerned and here's why.

Could an additive in your food be messing with the immune process that helps you fight off the flu after receiving the influenza vaccine?

Open Forum Infectious Disease study highlights workplace issues within the specialty.

Will biomarker-guided specific therapies the best option for treating sepsis in the future?

During a year-long study, 80 electronic conversational comments were made using the stewardship team’s audit-and-feedback tool and recommendations were fully adopted 90% of the time.

Oral ibrexafungerp demonstrates a favorable therapeutic response in patients with difficult-to-treat Candida infections, including those caused by non-albicans Candida species.

Lefamulin demonstrated non-inferiority when compared with moxifloxacin, and both treatment arms reported a low rate of serious treatment-emergent AEs or treatment-emergent AEs leading to discontinuation.

Cidara Therapeutics has developed CB-012, a stable conjugate of a highly potent antiviral agent linked to human IgG1 Fc, and investigators are evaluating the asset for the treatment and prevention of seasonal and pandemic influenza A and B infections.

The ASPECT-NP trial compared a new 3-gram dose regimen of ceftolozane/tazobactam versus meropenem in the treatment of ventilated nosocomial pneumonia.

Investigators found increased mortality in the combination arm where 21% of patients died vs 16% in the standard therapy arm, although the number of patients with persistent bacteremia at day 5 in the combination arm was significantly reduced compared with standard therapy.

A UK-based study team conducted an evaluation of real-time penicillin monitoring via minimally invasive, microneedle-based penicillin biosensor.

A study found that the molecule, Compound A, has potent activity against Acinetobacter Pneumonia in mice possibly by a dual killing mechanism and by reducing lipopolysaccharide-induced vascular leak.

Rezafungin achieved greater and more prolonged penetration at sites of intra-abdominal candidiasis than micafungin, which correlates with significantly greater activity against FKS-mutant Candida glabrata clinical strains.

A study found that eracavycline was 2-4-fold more active than tigecycline against isolates that produced ESBL and at least 8-fold more active than tigecycline against A baumannii.

Investigators detail the activity of cefiderocol, a novel parenteral siderophore cephalosporin, against carbapenem-resistant clinical isolates.

An Italian study found that immunization rates are high among health workers, but an important proportion of employees are not immune to mumps.

In a study of hospitalized patients across Europe, oritavancin (MIC50/MIC90, 0.03/0.06 mg/L) inhibited all S aureus isolates at ≤0.12 mg/L (susceptible breakpoint).

Ignacio Martin-Loeches, MD, PhD, discusses the efficacy outcomes of the ASPECT-NP trial evaluating ceftolozane/tazobactam for the treatment of nosocomial pneumonia.